Vaccine Safety Registry
Rotavirus Vaccine Safety
Institutional safety data for Rotavirus vaccines (RotaTeq, Rotarix). Clinical monitoring for intussusception, oral administration protocols, and surveillance metadata.
Medically reviewed by
Dr. Sanjay Iyer, MBBS, MD (General Medicine), DM (Gastroenterology)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Rotavirus is a highly contagious viral pathogen primary to severe diarrheal illness in pediatric cohorts. Pathological outcomes include acute pyrexia, emesis, and potentially life-threatening dehydration.
Prior to the introduction of the registry vaccines, rotavirus disease was ubiquitous, with virtually all children experiencing infection by age 5. Universal oral immunization has successfully suppressed incidence rates across the United States.
Vaccine Formulations
Module specifics & formulations
Formulation Node
RotaTeq
Merck | Pentavalent Protocol
- Titration: 3-dose oral series.
- Interval: 2, 4, and 6 months.
- Spectrum: Protects against 5 viral types.
- Protocol: Enteric oral administration.
Formulation Node
Rotarix
GSK | Monovalent Protocol
- Titration: 2-dose oral series.
- Interval: 2 and 4 months.
- Spectrum: High cross-protective efficacy.
- Efficiency: Faster completion of primary series.
Clinical Triage
Eligibility & contraindications
Routine Protocol
- All healthy infants (universal recommendation)
- Initial dose baseline by 15 weeks
- Final titration completion by 8 months
Age Limitations
- Minimum age: 6 weeks
- Maximum age for 1st dose: 14 weeks 6 days
- Maximum age for last dose: 8 months 0 days
Absolute & Relative Contraindications
- Anaphylaxis to previous rotavirus dose
- Severe combined immunodeficiency (SCID)
- History of intussusception (clinical priority)
- Acute moderate-to-severe illness state
Adverse Events
Reported reactions & surveillance
Standard Reactions
- Transient emesis (Vomiting)
- Mild, temporary diarrhea
- Minor pyrexia (Fever)
- Pediatric irritability
Critical Clinical Node
- Severe episodic abdominal pain
- Blood in stool (Currant jelly)
- Persistent emesis
- Lethargy / decreased alertness
Surveillance Analytics
Post-market surveillance metrics
2006
Registry Entry
80%+
Hospitalization Reduction
1-5 / 100k
Intussusception Probability
Institutional Synthesis
Since the synchronization of rotavirus protocols in 2006, institutional data confirms an 80% decrease in acute hospitalizations for rotavirus disease, maintaining a superior risk-to-benefit profile.
Editorial Governance
Clinical Reviewers & Authors
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Prevention of Rotavirus Gastroenteritis Among Infants and Children: Recommendations of the ACIP
MMWR Recommendations and Reports, 58(RR-2):1-25
- 2WHO2024Rotavirus vaccines: WHO position paper — July 2021
Weekly Epidemiological Record, 96(28):301-320
- 3FDA2024ROTARIX and ROTATEQ Package Inserts & Postmarketing Intussusception Surveillance
U.S. Food and Drug Administration CBER
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Sneha Rao and clinically reviewed by Dr. Sanjay Iyer, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.